Literature DB >> 12070030

Activation-induced cell death of aggressive histology lymphomas by CD40 stimulation: induction of bax.

Jamie L Szocinski1, Annette R Khaled, Julie Hixon, Douglas Halverson, Satoshi Funakoshi, William C Fanslow, Ann Boyd, Dennis D Taub, Scott K Durum, Clay B Siegall, Dan L Longo, William J Murphy.   

Abstract

CD40 is present on both normal and neoplastic B-lineage cells. CD40 stimulation of normal B cells has been shown to promote normal growth and differentiation, whereas aggressive histology B lymphomas are growth inhibited. The inhibition of neoplastic B-cell growth is believed to occur via activation-induced cell death in which stimuli that typically promote the growth of normal cells prevent the growth of their neoplastic counterparts. We show here that CD40 stimulation using either a soluble recombinant human CD40 ligand (srhCD40L) or anti-CD40 monoclonal antibody resulted in apoptosis of human Burkitt lymphoma cell lines. Additional studies examining the mechanism of CD40-mediated death revealed an increase in bax messenger RNA with a subsequent increase in Bax protein in the mitochondria of the treated cells. In vitro exposure of the cells to bax antisense oligonucleotides resulted in a significant decline in Bax protein levels and partial protection from CD40-mediated death, indicating that induction of Bax was at least one mechanism underlying this inhibitory effect of CD40 stimulation on lymphomas. When immunodeficient mice bearing Burkitt lymphoma were treated with srhCD40L, significant increases in survival were observed indicating a direct antitumor effect as a result of CD40 stimulation in vivo. Overall, these results demonstrate that CD40 ligation of aggressive histology B-lymphoma cells results in inhibition both in vitro and in vivo and thus may be of potential clinical use in their treatment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12070030     DOI: 10.1182/blood.v100.1.217

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

1.  To respond or not to respond to CD40 agonism: That is the prediction.

Authors:  Xiaoyan Shi; David Dornan
Journal:  Oncoimmunology       Date:  2012-01-01       Impact factor: 8.110

2.  Effects of environmentally-relevant levels of perfluorooctane sulfonate on clinical parameters and immunological functions in B6C3F1 mice.

Authors:  Patricia A Fair; Erin Driscoll; Meagan A M Mollenhauer; Sarah G Bradshaw; Se Hun Yun; Kurunthachalam Kannan; Gregory D Bossart; Deborah E Keil; Margie M Peden-Adams
Journal:  J Immunotoxicol       Date:  2011-01-24       Impact factor: 3.000

Review 3.  Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists.

Authors:  Gregory L Beatty; Yan Li; Kristen B Long
Journal:  Expert Rev Anticancer Ther       Date:  2016-12-14       Impact factor: 4.512

4.  CD40 blockade combines with CTLA4Ig and sirolimus to produce mixed chimerism in an MHC-defined rhesus macaque transplant model.

Authors:  A Page; S Srinivasan; K Singh; M Russell; K Hamby; T Deane; S Sen; L Stempora; F Leopardi; A A Price; E Strobert; K A Reimann; A D Kirk; C P Larsen; L S Kean
Journal:  Am J Transplant       Date:  2011-09-19       Impact factor: 8.086

5.  Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates.

Authors:  Sean K Kelley; Thomas Gelzleichter; Dong Xie; Wyne P Lee; Walter C Darbonne; Ferhan Qureshi; Kim Kissler; Ezogelin Oflazoglu; Iqbal S Grewal
Journal:  Br J Pharmacol       Date:  2006-07-10       Impact factor: 8.739

6.  CD40 activation in human pancreatic islets and ductal cells.

Authors:  D Klein; F Timoneri; H Ichii; C Ricordi; R L Pastori
Journal:  Diabetologia       Date:  2008-07-26       Impact factor: 10.122

7.  Inhibition of proliferation and induction of apoptosis in multiple myeloma cell lines by CD137 ligand signaling.

Authors:  Charles Gullo; Liang Kai Koh; Wan Lu Pang; Kian Tong Ho; Shi Hao Tan; Herbert Schwarz
Journal:  PLoS One       Date:  2010-05-26       Impact factor: 3.240

8.  Prognostic significance of CD40 expression in malignant lymphoma developing in rheumatoid arthritis.

Authors:  Toru Sasaki; Yoshihiko Hoshida; Jian-Xian Xu; Yasuhiko Tomita; Emi Sakane-Ishikawa; Shigeki Fujita; Katsuyuki Aozasa
Journal:  J Cancer Res Clin Oncol       Date:  2005-11-15       Impact factor: 4.322

9.  Novel targeted mtLivin nanoparticles treatment for disseminated diffuse large B-cell lymphoma.

Authors:  Ihab Abd-Elrahman; Taher Nassar; Noha Khairi; Riki Perlman; Simon Benita; Dina Ben Yehuda
Journal:  Oncogene       Date:  2020-10-30       Impact factor: 9.867

Review 10.  Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint.

Authors:  TingTing Tang; Xiang Cheng; Billy Truong; LiZhe Sun; XiaoFeng Yang; Hong Wang
Journal:  Pharmacol Ther       Date:  2020-10-20       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.